Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $65.00 price target on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $65.00 price target on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock.
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria [Yahoo! Finance]
MediumReport
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: